Absci
AbSci, LLC is a company specializing in protein production technologies for the biopharmaceutical industry, founded in 2011 and based in Portland, Oregon. The company has developed SoluPro, a genetically engineered E. coli-based expression system that facilitates the scalable production of antibodies, antibody fragments, and other soluble recombinant proteins at a significantly reduced cost. AbSci's therapeutic proteins are utilized in a variety of applications, including cancer treatment, hormone therapies, and therapies for autoimmune and blood disorders. The firm's innovative approach combines biologic drug discovery with cell line development, enhancing efficiency and flexibility in the manufacturing process while also accelerating drug discovery timelines. AbSci aims to position itself as a leader in the field by unlocking the potential of proteins as next-generation therapeutics.
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses.
It was founded in 2017 and is based in Cambridge, Massachusetts.
Developer of genome annotation and analytics software designed to accelerate innovation in biopharma. The company uses an AI-based approach for instant analysis and interpretation of large genomic data sets, allowing it to effectively support researchers in revolutionizing protein discovery by learning proteins at large.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.